Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-04-04

Clinical Trial Update: Efficacy and Safety of Botulinum Toxin at Moderate to Severe Glabellar Lines [Phase 3]

View source ↗

Summary

Phase 3 trial update on the efficacy and safety of botulinum toxin for moderate to severe glabellar lines has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Botulinum toxin (botulinum toxin)

Snippet

Sponsor: EuBiologics Co.,Ltd | Conditions: Glabellar Frown Lines | Phase 3 | Status: COMPLETED